Nava Therapeutics raised $89 million to advance a new class of lipid nanoparticles aimed at targeting bone marrow, immune cells, and the kidney. The startup, described as secretive, intends to use the financing to push its nanoparticle platform and associated programs toward further development, with the company targeting delivery challenges that have limited success for earlier systemic nanoparticle approaches.